Home > Riviste > Chirurgia > Fascicoli precedenti > Chirurgia 2018 December;31(6) > Chirurgia 2018 December;31(6):242-6

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Chirurgia 2018 December;31(6):242-6

DOI: 10.23736/S0394-9508.18.04800-3

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Outcome of isolated coronary surgery patients on dual antiplatelet therapy during the European suspension of aprotinin 2006-2014

Gunilla R. KJELLBERG 1 , Manne E. HOLM 1, Jan A. van der LINDEN 1, 2

1 Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; 2 Cardiothoracic Anesthesia and Intensive Care, Karolinska University Hospital, Stockholm, Sweden


PDF


BACKGROUND: Patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB) are at risk for excessive bleeding. Between 2008-2012, the European Medicines Agency suspended the marketing authorization of aprotinin, but Swedish hospitals received permission from national health authorities to continue to use it in a selected and controlled manner. The objective of this study was to compare the use of aprotinin in patients undergoing isolated CABG surgery during two time periods, 2006-2007 and 2008-2014, before and after aprotinin European suspension.
METHODS: We performed a retrospective analysis of collected data. All consecutive patients who underwent isolated CABG surgery with CPB and received aprotinin at a University Hospital between 2006 and 2014 were identified. Redo and combined procedures were excluded from the analysis.
RESULTS: After 2007, aprotinin administration was limited to patients taking clopidogrel and presenting with platelet aggregation <85% on the day of surgery. Use of aprotinin decreased substantially, from 113 patients/year 2006-2007 to 6 patients/year 2008-2014. Mean EuroSCORE I and mean CPB time were higher in the second period, reflecting a greater operative risk and a higher bleeding risk. No significant differences were observed regarding postoperative mortality, postoperative complications, intra- and postoperative bleeding and transfusion requirements.
CONCLUSIONS: The use of aprotinin decreased significantly after 2007 at a single cardiothoracic center. Despite a higher operative risk and a longer CPB time, patients receiving aprotinin between 2008 and 2014 had similar clinical outcomes and transfusion requirements as those treated with aprotinin during the prior two years.


KEY WORDS: Aprotinin - Hemostatics - Coronary artery bypass - Surgery

inizio pagina